Atty Dkt. No.: TOSK-004 USSN: 09/472,654

(a) contacting said compound composition with a population of from about 10 to 1000 small pon-mammalian multi-cellular organisms having a rapid generation time and differentiated organs and tissues; and

(b) determining the effect of said compound composition on said non-mammalian multi-cellular organisms;

wherein each of said/compound compositions is selected from the group consisting of: known pharmacologically active compounds and candidate pharmacologically active compounds.

12. (Amended) A high throughput antitoxin screening method in which at least 10 different candidate antitoxin compound compositions are simultaneously assayed for antitoxin activity, said method comprising:

simultaneously assaying at least 10 different candidate antitoxin compound compositions for antitoxin activity, wherein each of said at least 10 different candidate compound compositions is assayed for antitoxin activity by:

(a) contacting said candidate compound composition with a population of from about 10 to 1000 small non-mammalian multi-cellular organisms having a rapid generation time and differentiated organs and tissues which have been contacted with a toxin; and (b) determining the effect of said compound composition on said non-mammalian multi-cellular organisms.

## **REMARKS**

Claims 1 and 6 have been amended.

The above amendments to Claims 1 and 6 find support in the specification at page 7, lines 13 to 15. Claim 12 has been amended to correct a spelling error. As such, the above amendments introduce no new matter and their entry by the Examiner is respectfully requested.

Attached hereto is a marked up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."



22

Atty Dkt. No.: TOSK-004 USSN: 09/472,654

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: \_\_\_\_ 3 · 6 · 6 ·

Bret E. Field

Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

F:\DOCUMENT\tosk\004\preliminary amendment.doc



USSN: 09/472,654

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) A high throughput toxicology screening method in which at least 10 different compound compositions are simultaneously assayed for toxicity, said method comprising:

simultaneously assaying at least 10 different compound compositions for toxicity, wherein each of said at least 10 different compound compositions is assayed for toxicity by:

- (a) contacting said compound composition with a plurality of non-mammalian multi-cellular organisms; and
- (b) determining the effect of said compound composition on said non-mammalian multi-cellular organisms[.];

wherein each of said compound compositions is selected from the group consisting of: known pharmacologically active compounds, chemical analogs thereof, and new candidate pharmacologically active agents.

6. (Amended) A high throughput toxicology screening method in which at least 10 different compound compositions are simultaneously assayed for toxicity, said method comprising:

simultaneously assaying at least 10 different compound compositions for toxicity, wherein each of said at least 10 different compound compositions is assayed for toxicity by:

- (a) contacting said compound composition with a population of from about 10 to 1000 small non-mammalian multi-cellular organisms having a rapid generation time and differentiated organs and tissues; and
- (b) determining the effect of said compound composition on said non-mammalian multi-cellular organisms[.];

wherein each of said compound compositions is selected from the group consisting of: known pharmacologically active compounds, chemical analogs thereof, and candidate pharmacologically active agents.

12. (Amended) A high throughput antitoxin screening method in which at least 10 different candidate antitoxin compound compositions are simultaneously assayed for antitoxin activity, said method comprising:

simultaneously assaying at least 10 different candidate antitoxin compound compositions for

 $\times$ 

USSN: 09/472,654

antitoxin activity, wherein each of said at least 10 different candidate compound compositions is assayed for antitoxin activity by:

(a) contacting said [candiate] <u>candidate</u> compound composition with a population of from about 10 to 1000 small non-mammalian multi-cellular organisms having a rapid generation time and differentiated organs and tissues which have been contacted with a toxin; and

(b) determining the effect of said compound composition on said non-mammalian multicellular organisms.



USSN: 09/472,654

## CLEAN COPY OF COMPLETE SET OF AMENDED CLAIMS

1. A high throughput toxicology screening method in which at least 10 different compound compositions are simultaneously assayed for toxicity, said method comprising:

simultaneously assaying at least 10 different compound compositions for toxicity, wherein each of said at least 10 different compound compositions is assayed for toxicity by:

- (a) contacting said compound composition with a plurality of non-mammalian multi-cellular organisms; and
- (b) determining the effect of said compound composition on said non-mammalian multi-cellular organisms;

wherein each of said compound compositions is selected from the group consisting of: known pharmacologically active compounds, chemical analogs thereof, and new candidate pharmacologically active agents.

- 2. The screening method according to Claim 1, wherein said plurality of non-mammalian multicellular organisms ranges from about 10 to 1000.
- 3. The screening method according to Claim 1, wherein said non-mammalian multi-cellular organisms have a rapid generation time.
- 4. The screening method according to Claim 1, wherein said non-mammalian multi-cellular organisms are small.
- 5. The screening method according to Claim 1, wherein said non-mammalian multi-cellular organisms are characterized by the presence of differentiated organs and tissues.
- 6. A high throughput toxicology screening method in which at least 10 different compound compositions are simultaneously assayed for toxicity, said method comprising:

simultaneously assaying at least 10 different compound compositions for toxicity, wherein each of said at least 10 different compound compositions is assayed for toxicity by:

(a) contacting said compound composition with a population of from about 10 to 1000 small



USSN: 09/472,654

non-mammalian multi-cellular organisms having a rapid generation time and differentiated organs and tissues; and

(b) determining the effect of said compound composition on said non-mammalian multi-cellular organisms;

wherein each of said compound compositions is selected from the group consisting of: known pharmacologically active compounds, chemical analogs thereof, and candidate pharmacologically active agents.

- 7. The method according to Claim 6, wherein said population is characterized by producing at least 100 progeny per day.
- 8. The method according to Claim 6, wherein at least 100 compound compositions are tested simultaneously.
- 9. The method according to Claim 6, wherein at least 1000 compound compositions are tested simultaneously.
- 10. The method according to Claim 6, wherein said multi-cellular organism is an insect.
- 11. The method according to Claim 10, wherein said insect is a fly.
- 12. A high throughput antitoxin screening method in which at least 10 different candidate antitoxin compound compositions are simultaneously assayed for antitoxin activity, said method comprising:

simultaneously assaying at least 10 different candidate antitoxin compound compositions for antitoxin activity, wherein each of said at least 10 different candidate compound compositions is assayed for antitoxin activity by:

(a) contacting said candidate compound composition with a population of from about 10 to 1000 small non-mammalian multi-cellular organisms having a rapid generation time and differentiated organs and tissues which have been contacted with a toxin; and (b) determining the effect of said compound composition on said non-mammalian multi-cellular organisms.



USSN: 09/472,654

13. The method according to Claim 12, wherein said population is characterized by producing at least 100 progeny per day.

- 14. The method according to Claim 12, wherein at least 100 candidate compound compositions are tested simultaneously.
- 15. The method according to Claim 6, wherein at least 1000 candidate compound compositions are tested simultaneously.
- 16. The method according to Claim 6, wherein said multi-cellular organism is an insect.
- 17. A database of toxicity profiles, said database comprising a plurality of toxicity profiles for a plurality of compounds.
- 18. A database according to Claim 17, wherein said database is prepared by compiling toxicity profiles generated according to the method of Claim 1.
- 19. The database according to Claim 17, wherein said database is present on a computer readable medium.
- 20. The database according to Claim 17, wherein said database comprises at least 10 different toxicity profiles.

